Avantor, Inc. · AVTR · FY2025 Q3 · Calendar Q4 2025

Avantor Q3: Revenue decline deepens as management launches a turnaround plan

The Q3 update weakens the near-term operating case: Avantor reported a 5% organic revenue decline and lowered its full-year outlook again, following the prior quarter’s already reduced forecast. Management’s Avantor Revival plan and cost-savings target offer a response, but execution, lab share losses, pricing pressure and supply-chain reliability remain unresolved.

Reported Before market openNYSEHealthcare $10.88B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $0.22 Consensus $0.22
EPS surprise -2.1% Reported versus consensus
Reported revenue $1.62B Consensus $1.65B
Revenue surprise -1.3% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move -23.2% Event window
SPY move +0.0% Same window
Abnormal move -23.3% Stock minus SPY
Volume 3.1× Versus trailing sessions
Subsequent drift +1.4% Up to 20 sessions
AVTRSPY benchmark

Ask FN2 about AVTR FY2025 Q3

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Compared with the prior-quarter picture of flat Q2 revenue and a full-year organic-growth outlook of -2% to 0%, management’s Q3 analysis reports a 5% organic revenue decline and a revised 2025 organic-growth outlook of -3.5% to -2.5%. Management introduced the five-pillar Avantor Revival program. The supplied Q3 analysis also records a $785 million goodwill impairment on the lab distribution business and board authorization of a $500 million share repurchase program.

Guidance delta

Management lowered its 2025 organic revenue growth outlook to -3.5% to -2.5%, from the prior-quarter range of -2% to 0%.

Key takeaways

  • Q3 organic revenue declined 5%, with the lab segment weaker than expected.
  • Management lowered its full-year 2025 organic-growth outlook to -3.5% to -2.5%.
  • Avantor Revival centers on go-to-market changes, manufacturing, portfolio focus, cost reduction and talent.
  • The analysis notes a $785 million goodwill impairment on the lab distribution business and a newly authorized $500 million repurchase program.

Management priorities

  • Execute the five-pillar Avantor Revival program across commercial operations, manufacturing, portfolio, cost and talent.
  • Invest in manufacturing upgrades and supply-chain reliability.
  • Rework brand architecture and expand e-commerce capabilities.
  • Continue the cost transformation program, which targets $400 million in run-rate savings by 2027.

Follow AVTR with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
AVTR EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q2 '24 estimate $0.23 Q2 '24 actual $0.25, beat Q3 '24 estimate $0.25 Q3 '24 actual $0.26, match Q2 '25 estimate $0.25 Q2 '25 actual $0.24, match Q3 '25 estimate $0.22 Q3 '25 actual $0.22, match Q4 '25 estimate $0.21 Q4 '25 actual $0.22, match Q1 '26 estimate $0.16 Q1 '26 actual $0.17, beat Q2 '26 estimate $0.19 Q2 '26 actual $0.21, beat Q3 '26 estimate $0.21 Q3 '26 actual $0.22, beat Q4 '26 estimate $0.22 Q1 '27 estimate $0.19 Q2 '27 estimate $0.23 Q3 '27 estimate $0.23
Show 2 more >

Analyst Consensus ?

ConsensusHold25 ratings
Bullish728.0%
Neutral1664.0%
Bearish28.0%

Analyst 52W Price Targets

$16.05Current
$7Low
$20.05Average
$50High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 2, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Stifel Hold HoldMaintainOct 29, 2026
RBC Capital Sector Perform Sector PerformMaintainOct 29, 2026
Barclays Underweight UnderweightMaintainOct 29, 2026
Baird Outperform OutperformMaintainOct 29, 2026
TD Cowen Hold HoldMaintainOct 13, 2026
Morgan Stanley Equal Weight Equal WeightMaintainOct 13, 2026
UBS Neutral NeutralMaintainSep 9, 2026
Wells Fargo Overweight OverweightMaintainJul 30, 2026
Evercore ISI Group In Line In LineMaintainJul 30, 2026
Citigroup Neutral NeutralMaintainJul 8, 2026
Jefferies Underperform HoldDowngradeDec 17, 2025
JP Morgan Neutral OverweightDowngradeOct 30, 2025
Raymond James Outperform OutperformMaintainOct 16, 2025
Goldman Sachs Neutral BuyDowngradeApr 29, 2025
Deutsche Bank Hold HoldMaintainApr 18, 2024
William Blair Market Perform OutperformDowngradeJul 31, 2023
Credit Suisse Neutral NeutralMaintainJul 31, 2023
B of A Securities Buy BuyMaintainJul 31, 2023
Keybanc Overweight OverweightMaintainSep 15, 2022
Cowen & Co. Market Perform OutperformDowngradeSep 14, 2022
Cleveland Research Neutral BuyDowngradeSep 9, 2022
Piper Sandler Overweight NeutralUpgradeAug 2, 2021
Stifel Nicolaus Hold HoldMaintainNov 15, 2019
Janney Capital Buy BuyMaintainJun 14, 2019
Piper Jaffray Neutral NeutralMaintainJun 11, 2019
Show less

Named analyst price targets

Upside is calculated against the persisted current price $16.05. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Deutsche BankAnalyst unavailable$17$16.46 +5.9%Oct 29, 2026
Robert W. BairdAnalyst unavailable$18$16.69 +12.1%Oct 29, 2026
BarclaysAnalyst unavailable$16$16.69 -0.3%Oct 29, 2026
Evercore ISIAnalyst unavailable$17$16.69 +5.9%Oct 28, 2026
RBC CapitalDan Leonard$17$16.69 +5.9%Oct 28, 2026
UBSDoug Schenkel$16$15.25 -0.3%Sep 9, 2026
Morgan StanleyAnalyst unavailable$14$13.66 -12.8%Jul 30, 2026
RBC CapitalDan Leonard$14$13.98 -12.8%Jul 30, 2026
Deutsche BankAnalyst unavailable$13$14.06 -19.0%Jul 30, 2026
JefferiesAnalyst unavailable$13$14.38 -19.0%Jul 29, 2026
Evercore ISIAnalyst unavailable$10.5$10.4 -34.6%Jul 6, 2026
BernsteinAnalyst unavailable$10.5$10.08 -34.6%Jun 26, 2026
UBSAnalyst unavailable$8$9.43 -50.2%Jun 24, 2026
Wolfe ResearchAnalyst unavailable$7$9.19 -56.4%Jun 1, 2026
RBC CapitalAnalyst unavailable$9$7.94 -43.9%May 14, 2026
BarclaysAnalyst unavailable$7$8.18 -56.4%Apr 14, 2026
Morgan StanleyAnalyst unavailable$10$9.38 -37.7%Feb 13, 2026
UBSDan Leonard$10.5$9.34 -34.6%Feb 12, 2026
Stifel NicolausAnalyst unavailable$10$9.24 -37.7%Feb 12, 2026
JefferiesTycho Peterson$8$9.24 -50.2%Feb 12, 2026
BarclaysAnalyst unavailable$9$9.64 -43.9%Feb 12, 2026
Robert W. BairdAnalyst unavailable$11$9.64 -31.5%Feb 12, 2026
Evercore ISIVijay Kumar$10$9.32 -37.7%Feb 11, 2026
Evercore ISIAnalyst unavailable$12$11.46 -25.2%Jan 5, 2026
JefferiesTycho Peterson$9$11.2 -43.9%Dec 17, 2025
BarclaysLuke Sergott$12$11.58 -25.2%Oct 30, 2025
UBSAnalyst unavailable$12$11.58 -25.2%Oct 30, 2025
BarclaysLuke Sergott$15$13.67 -6.5%Oct 2, 2025
Stifel NicolausAnalyst unavailable$12$11.3 -25.2%Aug 4, 2025
Raymond JamesAnalyst unavailable$14$11.3 -12.8%Aug 4, 2025
Robert W. BairdAnalyst unavailable$17$12.49 +5.9%Apr 28, 2025
Morgan StanleyTejas Savant$15$12.93 -6.5%Apr 28, 2025
BarclaysLuke Sergott$26$21.87 +62.0%Feb 3, 2025
BernsteinEve Burstein$24.5$21.66 +52.6%Jan 10, 2025
Evercore ISIVijay Kumar$26$21.2 +62.0%Jan 2, 2025
Robert W. BairdCatherine Schulte$26$22.56 +62.0%Oct 28, 2024
Morgan StanleyTejas Savant$28$24.4 +74.5%Oct 21, 2024
Robert W. BairdCatherine Schulte$27$26.02 +68.2%Jul 29, 2024
Evercore ISIVijay Kumar$27.5$25.6 +71.3%Jul 26, 2024
Evercore ISIVijay Kumar$27$20.77 +68.2%Jul 2, 2024
JefferiesTycho Peterson$28$24.08 +74.5%Jun 3, 2024
Deutsche BankJustin Bowers$25$24.38 +55.8%Apr 18, 2024
Raymond JamesAndrew Cooper$30$23.05 +86.9%Feb 5, 2023
Raymond JamesAndrew Cooper$36$28.34 +124.3%Aug 9, 2022
Robert W. BairdCatherine Schulte$34$28.34 +111.8%Aug 8, 2022
BarclaysLuke Sergott$33$28.67 +105.6%Aug 4, 2022
Wells FargoAnalyst unavailable$33$29.95 +105.6%Apr 25, 2022
Stifel NicolausDaniel Arias$46$42.33 +186.6%Sep 10, 2021
Credit SuisseKatie Tryhane$50$42.33 +211.5%Sep 10, 2021
GuggenheimSandy Draper$45$37.6 +180.4%Aug 2, 2021
Morgan StanleyTejas Savant$44$37.6 +174.1%Aug 2, 2021
Goldman SachsMatthew Sykes$40$31.3 +149.2%Jun 4, 2021
Show less

Track every rating change on AVTR the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample…

Historical context

All AVTR earnings

Healthcare peers this season

Latest reports in the same sector

Latest beats and misses

Who reports next

Get the AVTR recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-11-02T02:00:43.346396+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-02T02:00:43.343493+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-11-02. For educational purposes only; not investment advice.